SPOTLIGHT: PDI loses GSK contract

PDI says that GlaxoSmithKline isn't renewing its contract sales deal for 2007, ending an arrangement that was worth $65 million to $70 million a year in revenue, a big chunk of its income. PDI's total revenue last year was $319 million. PDI CEO Michael Marquardt said the company's immediate priority is finding new opportunities for the sales force that had been deployed for GSK products. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.